Education
About Us
Working with TipRanks
Follow Us
Innate Pharma SA (IPHYF)
OTHER OTC:IPHYF
Earnings Data
Report Date
Sep 17, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.36Last Year’s EPS
-0.34Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 27, 2025
|% Change Since: -39.31%
|Next Earnings Date:Sep 17, 2025
Earnings Call Sentiment|Positive
Innate Pharma showcased significant progress in advancing their clinical pipeline, particularly with the recruitment and dosing of key assets like IPH65 and IPH45, and the FDA breakthrough designation for lacutamab. Financial stability and strategic focus on NK cell engagers and ADCs were emphasized. However, challenges remain with reduced R&D expenses, ongoing partnering discussions for lacutamab, and the shift in focus for IPH6401. Overall, the highlights and achievements appear to outweigh the lowlights.Company Guidance
During the Innate Pharma Full Year 2024 Financial Results and Business Update call, significant progress and future guidance were highlighted. The company advanced its IPH65 program, recruiting the first patients into a Phase 1 trial in early 2024, with data expected by year-end or early 2025. The IPH45 program also progressed, with the first patients dosed in January 2025 following IND clearance in September 2024. Lacutamab received breakthrough therapy designation from the FDA, moving closer to accelerated approval. Financially, Innate reported EUR20.1 million in revenue for 2024, primarily from collaboration agreements, and maintained EUR91.1 million in available cash, ensuring operation funding through mid-2026. The strategic focus includes advancing the ANKET platform, antibody drug conjugates, and late-stage assets, with partnerships playing a critical role in future developments.Phase 1 Dose Finding Trial Recruitment for IPH65
The first patients were recruited into the Phase 1 dose finding trial for IPH65 in the first half of 2024, marking a critical step in its clinical development.
FDA Breakthrough Therapy Designation for Lacutamab
Lacutamab received FDA breakthrough therapy designation, bringing it closer to potential accelerated approval for treating Sezary syndrome.
First Patients Dosed for IPH45
The first patients were dosed for the Nectin-4 targeted ADC, IPH45, in January 2025, following the IND clearance in September 2024.
Strong Pipeline and Strategic Focus
Innate Pharma is advancing a robust pipeline with eight innovative assets in the clinic, focusing on NK cell engagers, ADCs, and late-stage assets like lacutamab.
Financial Stability Through Mid-2026
Cash, cash equivalent, short-term investments, and financial assets amounted to EUR91.1 million as of December 31, 2024, providing sufficient funds through mid-2026.
---
IPHYF Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
IPHYF Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 27, 2025 | $2.90 | $2.90 | 0.00% |
| Sep 12, 2024 | $2.40 | $2.32 | -3.33% |
| Mar 21, 2024 | $2.38 | $2.36 | -0.84% |
| Sep 14, 2023 | $3.04 | $2.98 | -1.97% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Innate Pharma SA (IPHYF) report earnings?
Innate Pharma SA (IPHYF) is schdueled to report earning on Sep 17, 2025, TBA Not Confirmed.
What is Innate Pharma SA (IPHYF) earnings time?
Innate Pharma SA (IPHYF) earnings time is at Sep 17, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is IPHYF EPS forecast?
IPHYF EPS forecast for the fiscal quarter 2025 (Q2) is -0.36.
---